Literature DB >> 29196213

Ifngr1 and Stat1 mediated canonical Ifn-γ signaling drives nigrostriatal degeneration.

Michael R Strickland1, Emily J Koller2, Doris Z Deng1, Carolina Ceballos-Diaz2, Todd E Golde3, Paramita Chakrabarty4.   

Abstract

Brain expression of AAV-Ifn-γ leads to reactive gliosis, nigrostriatal degeneration and midbrain calcification in wild type mice. This mouse model phenocopies idiopathic basal ganglia calcification which is associated with Parkinsonian symptoms. To understand how the nigro-striatal pathway is selectively vulnerable to Ifn-γ, we determined if the phenotype is driven by canonical signaling intermediates, Ifngr1 and Stat1. Using focused bioinformatic analysis and rotarod testing, we show that neuroinflammation and motor abnormalities precede the appearance of midbrain neuropathologies in the brains of Ifn-γ mouse model. To test whether canonical Ifn-γ signaling is a key driver of progressive nigrostriatal degeneration, we overexpressed Ifn-γ in the brains of Ifngr1-/- and Stat1-/- mice. Expression of Ifn-γ in Ifngr1-/- mice did not result in any neuroinflammation, midbrain calcinosis or nigrostriatal degenerative pathology. Interestingly, in Stat1-/- mice, Ifn-γ expression resulted in gliosis without recapitulating the neurodegenerative phenotype. Overall, our data shows that canonical Ifn-γ signaling triggers midbrain calcinosis and nigrostriatal neurodegeneration, providing mechanistic insights into cytokine-driven selective neuronal vulnerability. Our study establishes the broader relevance of inflammatory signaling in neurodegenerative diseases and can potentially identify novel immunological targets for Parkinsonian syndromes.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Canonical Ifn-γ signaling; Neurodegeneration; Neuroinflammation; Nigro-striatal pathway

Mesh:

Substances:

Year:  2017        PMID: 29196213      PMCID: PMC5748010          DOI: 10.1016/j.nbd.2017.11.007

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  30 in total

Review 1.  Complexity and heterogeneity: what drives the ever-changing brain in Huntington's disease?

Authors:  H Diana Rosas; David H Salat; Stephanie Y Lee; Alexandra K Zaleta; Nathanael Hevelone; Steven M Hersch
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

Review 2.  Current prospects of type II interferon γ signaling and autoimmunity.

Authors:  Daniel S Green; Howard A Young; Julio C Valencia
Journal:  J Biol Chem       Date:  2017-06-26       Impact factor: 5.157

Review 3.  Ageing, neurodegeneration and brain rejuvenation.

Authors:  Tony Wyss-Coray
Journal:  Nature       Date:  2016-11-10       Impact factor: 49.962

Review 4.  Molecular biology of amyotrophic lateral sclerosis: insights from genetics.

Authors:  Piera Pasinelli; Robert H Brown
Journal:  Nat Rev Neurosci       Date:  2006-09       Impact factor: 34.870

5.  IL-10 alters immunoproteostasis in APP mice, increasing plaque burden and worsening cognitive behavior.

Authors:  Paramita Chakrabarty; Andrew Li; Carolina Ceballos-Diaz; James A Eddy; Cory C Funk; Brenda Moore; Nadia DiNunno; Awilda M Rosario; Pedro E Cruz; Christophe Verbeeck; Amanda Sacino; Sarah Nix; Christopher Janus; Nathan D Price; Pritam Das; Todd E Golde
Journal:  Neuron       Date:  2015-01-22       Impact factor: 17.173

Review 6.  Components of the IFN-gamma signaling pathway in tumorigenesis.

Authors:  George Blanck
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2002       Impact factor: 4.291

7.  Interferon-gamma directly induces neurotoxicity through a neuron specific, calcium-permeable complex of IFN-gamma receptor and AMPA GluR1 receptor.

Authors:  Tetsuya Mizuno; Guiqin Zhang; Hideyuki Takeuchi; Jun Kawanokuchi; Jinyan Wang; Yoshifumi Sonobe; Shijie Jin; Naoki Takada; Yukio Komatsu; Akio Suzumura
Journal:  FASEB J       Date:  2008-01-15       Impact factor: 5.191

Review 8.  Alzheimer's disease selective vulnerability and modeling in transgenic mice.

Authors:  Jürgen Götz; Nicole Schonrock; Bryce Vissel; Lars M Ittner
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

9.  Capsid serotype and timing of injection determines AAV transduction in the neonatal mice brain.

Authors:  Paramita Chakrabarty; Awilda Rosario; Pedro Cruz; Zoe Siemienski; Carolina Ceballos-Diaz; Keith Crosby; Karen Jansen; David R Borchelt; Ji-Yoen Kim; Joanna L Jankowsky; Todd E Golde; Yona Levites
Journal:  PLoS One       Date:  2013-06-25       Impact factor: 3.240

10.  MHC-I expression renders catecholaminergic neurons susceptible to T-cell-mediated degeneration.

Authors:  Carolina Cebrián; Fabio A Zucca; Pierluigi Mauri; Julius A Steinbeck; Lorenz Studer; Clemens R Scherzer; Ellen Kanter; Sadna Budhu; Jonathan Mandelbaum; Jean P Vonsattel; Luigi Zecca; John D Loike; David Sulzer
Journal:  Nat Commun       Date:  2014-04-16       Impact factor: 14.919

View more
  3 in total

1.  Combining P301L and S320F tau variants produces a novel accelerated model of tauopathy.

Authors:  Emily J Koller; Elsa Gonzalez De La Cruz; Timothy Machula; Kristen R Ibanez; Wen-Lang Lin; Tosha Williams; Cara J Riffe; Daniel Ryu; Kevin H Strang; Xuefei Liu; Christopher Janus; Todd E Golde; Dennis Dickson; Benoit I Giasson; Paramita Chakrabarty
Journal:  Hum Mol Genet       Date:  2019-10-01       Impact factor: 6.150

2.  Diffusion magnetic resonance imaging-derived free water detects neurodegenerative pattern induced by interferon-γ.

Authors:  Marcelo Febo; Pablo D Perez; Carolina Ceballos-Diaz; Luis M Colon-Perez; Huadong Zeng; Edward Ofori; Todd E Golde; David E Vaillancourt; Paramita Chakrabarty
Journal:  Brain Struct Funct       Date:  2020-01-01       Impact factor: 3.270

3.  Different genes may be involved in distal and local sensitization: A genome-wide gene-based association study and meta-analysis.

Authors:  Afroditi Kouraki; Michael Doherty; Gwen S Fernandes; Weiya Zhang; David A Walsh; Anthony Kelly; Ana M Valdes
Journal:  Eur J Pain       Date:  2022-01-07       Impact factor: 3.651

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.